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Background: Cancer-related disturbances in myeloid lineage development, marked by high levels of myeloid-derived
suppressor cells (MDSC) and impaired dendritic cell (DC) development, are associated with poor clinical outcome due
to immune escape and therapy resistance. Redressing this balance may therefore be of clinical benefit. Here we
investigated the effects of combined Prostate GVAX/ipilimumab immunotherapy on myeloid subsets in peripheral
blood of castration-resistant prostate cancer (CRPC) patients as well as the putative predictive value of baseline
and on-treatment myeloid parameters on clinical outcome.
Methods: Patients with CRPC (n = 28) received thirteen intradermal administrations of Prostate GVAX, consisting
of two allogeneic GM-CSF-transduced and irradiated prostate cancer cell lines (LN-CaP and PC3) and six infusions
of escalating doses of anti-CTLA4/ipilimumab. Frequencies and activation status of peripheral blood DC (PBDC)
and MDSC were determined before, during and after treatment by flowcytometric analysis and related to clinical
benefit.
Results: Significant treatment-induced activation of conventional and plasmacytoid DC subsets (cDC and pDC)
was observed, which in the case of BDCA1/CD1c+ cDC1 and MDC8+/6-sulfoLacNAc+ inflammatory cDC3 was
associated with significantly prolonged overall survival (OS), but also with the development of autoimmune-related
adverse events. High pre-treatment levels of CD14+HLA-DR−monocytic MDSC (mMDSC) were associated with reduced
OS. Unsupervised clustering of these myeloid biomarkers revealed particular survival advantage in a group of patients
with high treatment-induced PBDC activation and low pretreatment frequencies of suppressive mMDSC in conjunction
with our previously identified lymphoid biomarker of high pretreatment CD4+CTLA4+ T cell frequencies.
Conclusions: Our data demonstrate that DC and MDSC subsets are affected by prostate GVAX/ipilimumab therapy
and that myeloid profiling may contribute to the identification of patients with possible clinical benefit of Prostate
GVAX/ipilimumab treatment.
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Prostate cancer is the third leading cause of cancer-
related death in men worldwide [1]. Curative treatment
options are only available for localized disease. In pa-
tients that develop metastatic castration-resistant prostate
cancer (mCRPC) the median survival is 16-21 months
[2-4]. Recent advances have led to novel immunotherapy
options with proven clinical efficacy in patients with
metastatic CRPC (mCRPC), such as PROSTVAC and
Sipuleucel-T [1,3,4]. In addition, the CTLA-4 blocking
antibody ipilimumab has shown clinical activity in a
variety of cancer types, including prostate cancer [5-7].
CTLA-4 blockade enhanced antitumor efficacy when
combined with other immunomodulating agents, in-
cluding Granulocyte Macrophage-Colony Stimulating
Factor (GM-CSF) and GM-CSF-secreting cancer vac-
cines, e.g. GVAX immunotherapy [8-10]. In line with
this, we recently reported the combined immunotherapy
of a GM-CSF-engineered allogeneic tumor cell-based vac-
cine (Prostate GVAX) and ipilimumab in patients with
mCRPC to be safe and clinically active [11]; clinical results
included partial responses (PR) and a relatively long sur-
vival as compared to survival rates observed in control
arms of recent Phase III trials [2-4].
Recent clinical findings have indicated that the induc-
tion of an effective antitumor immune response relies
on the proper differentiation, maturation and functional-
ity of myeloid antigen-presenting cells (APC), and that
the accumulation of myeloid-derived suppressor cells
(MDSC) and functionally impaired (immature) dendritic
cells (DC) in tumor, blood or lymph nodes of cancer pa-
tients is a poor prognostic factor for survival [12-16].
Therefore, cancer immunotherapeutic approaches aiming
at the normalization of myeloid differentiation are of inter-
est for clinical application in support of immunotherapy.
We have reported the effects of prostate GVAX/
ipilimumab immunotherapy on circulating T cell sub-
sets [17]. However, the net effect of combined prostate
GVAX/ipilimumab immunotherapy on DC and MDSC
subsets in peripheral blood is currently unknown. It
has been described that under proper maturational
conditions, peripheral blood DC (PBDC) have the po-
tential to develop into functional DC with the capacity
to induce antitumor T-cell responses [18,19]. In par-
ticular GM-CSF has been implicated in the recruit-
ment and activation of DC in vivo [20,21]. Importantly
however, GM-CSF has also been linked to the systemic in-
duction/expansion of MDSC in mice and man [22,23].
Furthermore, CTLA-4 antibody blockade has been shown
to reduce MDSC suppressive potency in vitro, and in vivo
in a murine ovarian carcinoma model, and this effect was
achieved both indirectly through inhibiting T cell-MDSC
interaction [24,25] and directly through binding to CTLA-
4 expressed on MDSC [26].To study whether PBDC and MDSC subsets are af-
fected by prostate GVAX/ipilimumab therapy, extensive
myeloid subset monitoring was performed. Myeloid sub-
sets were analyzed prospectively and followed during
treatment, after which cut-off points for response to
treatment and/or survival were determined in retrospect.
Our data demonstrate that PBDC are activated by pros-
tate GVAX/ipilimumab therapy and that a specific mye-
loid lineage marker profile (i.e. high post-treatment cDC
activation and low pre-treatment frequencies of mono-
cytic MDSC) proved predictive for clinical benefit after
Prostate GVAX and/or ipilimumab immunotherapy.
Results
Clinical results
mCRPC patients (n = 28) received 13 bi-weekly injec-
tions of the prostate GVAX vaccine and 6 four-weekly
infusions of ipilimumab. As described previously [11],
five patients experienced serum-PSA-based PR with PSA
declines of more than 50% and 12 demonstrated disease
stabilization (SD); PR/SD was significantly correlated
with prolonged overall survival (med. survival of 41 ver-
sus 21 months; p = 0.0034). Nine patients, all of which
received 3 or 5 mg/kg ipilimumab and five of which ex-
perienced a PR, developed immune-related adverse
events (IRAE) [11]. Interestingly, although IRAE were
more frequent in patients that benefited from treatment
(i.e. PR and SD; p = 0.0015), the development of IRAE
was not associated with survival ([11]; Additional file 1:
Figure S1).
PBDC and monocyte frequency and activation in relation
to survival and IRAE
To assess the effects of prostate GVAX/ipilimumab treat-
ment on circulating myeloid DC subsets, frequency and
activation status of circulating conventional DC (cDC)
subsets cDC1, cDC2, cDC3 and plasmacytoid DC (pDC)
were determined before, during and after treatment. cDC1
were identified as CD11chiCD19−CD14−BDCA-1/CD1c+;
cDC2 as CD11c+CD14−BDCA-3+; cDC3 as CD11chiC-
D14loMDC8+ and pDC as CD11c−CD14−CD123hiBDCA-
2+ (see also Additional file 2: Figure S2 for gating
strategies). Similar to previous observations in cancer
patients by us and by others [12,15,27,28], frequencies
and activation status of circulating DC and monocytes
were generally lower in CRPC patients as compared
with healthy individuals (see Additional file 3: Figure S3A
and 3B). On-treatment activation (shown in Figure 1A by
CD40 expression levels) was observed for all DC subsets
(as previously reported by us for cDC1 [11]). Interestingly,
this activation was paralleled by decreases in cDC1, cDC2,
and pDC frequencies (Figure 1B). These decreases were
observed as early as four weeks after start of treatment
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Figure 1 Prostate GVAX/ipilimumab therapy-induced activation of peripheral blood (PB) DC subsets is associated with prolonged
survival. PBDC activation and frequency was determined before (week 0/visit 1 (w0v1)), during (w4v3, w8v5, w12v7, w16v9, w20v11, w24v13 and
after (follow-up (fu)) prostate GVAX/ipilimumab therapy by flow cytometry. A) Activation state over treatment –by Median Fluorescence Index
(MFI) of CD40 of CD11chiCD19−CD14loBDCA1+cDC1, CD11c+CD14−BDCA-3+ cDC2, CD11c+CD14loMDC8+ cDC3 and CD11c−CD14−CD123hiBDCA-2+pDC.
Grey bars denote the mean ± SEM range at baseline. B) DC subset frequencies (as percentages of PBMC) and C) absolute numbers per ml blood, over
treatment, cDC1: solid black squares, cDC2: open black squares, cDC3: solid grey squares, pDC: open grey squares. Means ± SEM of 28 patients are
shown. D) Kaplan Meier curve for on-treatment increases in cDC1 and cDC3 activation. Number of patients and corresponding median survival
for each group is given. Differences between pre- and on- or post-treatment were analyzed with the repeated measures ANOVA with a
post-hoc Dunnett’s multiple comparisons test. Differences were considered significant when p < 0.05, as indicated with asterisks (* p < 0.05,
** p < 0.01) within the respective squares. Statistical significance of the survival distribution was analyzed by log-rank testing.
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bers per volume blood were much less pronounced and
on-treatment increased absolute cDC3 numbers evenreached significance (Figure 1C). These differences be-
tween DC frequencies and absolute numbers may in large
part be explained by a sustained increase in absolute
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Additional file 4: Figure S4). Increased PBDC activation
was generally maintained during treatment (see Figure 1A)
and increases of >70% of CD40 med. FI on the cDC1
and cDC3 subsets (see for representative histograms
Additional file 2: Figure S2) were associated with signifi-
cantly prolonged overall survival (OS; median survival
38.5 vs. 15.5 months, p = 0.0004 and median survival 40
vs. 19 months, p = 0.0031, respectively (Table 1). Survival
benefit was even more pronounced for patients who dis-
played treatment-induced activation of both cDC1 and
cDC3 subsets (median survival 52 vs. 16 months, p <
0.0001; Figure 1C). No relationship with survival was
found for either pDC or cDC2.
When patients were divided by treatment response,
decreases in the frequency of monocytes were found to
be selectively associated with PR (Figure 2A), which, like
observed for PBDC subsets, was paralleled by increased
activation (Figure 2B). Of note, although these were
clear trends, they did not reach statistical significance.
Similarly to the cDC1/BDCA1 and cDC3/SLAN-DC
subsets, treatment-induced increases of CD40 med. FI
on CD14+ monocytes was associated with prolonged OS
(median survival 57 vs. 21 months, p = 0.0749; Figure 2C
and Table 1).
To determine whether changes in DC and monocyte
activation status could possibly serve as early marker for
the ipilimumab-associated development of IRAE, we
compared the rise in DC or monocyte activation status at
week four of treatment (i.e. after two GVAX administra-
tions and only one ipilimumab infusion) between patients
with or without IRAE. As shown in Figure 3, treatment-
induced increases in cDC1, cDC3, and monocyteTable 1 Characteristics and survival distribution of treatment
frequencies






CD40 on cDC1 313% (-67 to +1194) 70% 38.5 vs. 15.5(2
CD40 on cDC2 170% (-52 to +612) 150% 36.5 vs. 25.5 (
CD40 on cDC3 160% (-16 to +765) 70% 40.0 vs. 19.0 (
CD40 on pDC 290% (-19 to +1814) 450% 26.0 vs. 31.5 (
CD40 on monocytes 243% (-28 to +1001) 160% 57.0 vs. 21.0 (
Lin-CD14+HLA-DR−mMDSC 87% (-71 to +543) 60% 35.0 vs. 36.0 (
*Mean and range of treatment-induced increases are given in percentages relative
†Cut-off points for survival prediction were determined using the Cox regression m
pre-treatment values.
‡Median Survival for both groups was calculated using the Kaplan-Meier method an
§Statistical significance of the survival distribution was analyzed by log-rank testing
¶Mean Halabi Predicted Survival (HPS) ± standard error (in months) was determined
NB: Halabi scores were determined based on Halabi et al. J. Clin. Oncol. 2003 [29], b
prognosis before treatment (based on HPS) not to be the determining factor for an
treatment (not shown).
׀׀ Differences in HPS between groups were determined by Mann-Whitney U test andactivation were significantly higher in patients that eventu-
ally developed IRAE, suggesting that these treatment-
induced increases might serve as an indicator for risk of
IRAE.
MDSC frequencies in relation to survival
To assess the effects of prostate GVAX/ipilimumab
treatment on circulating MDSC, the frequency of mono-
cytoid MDSC (mMDSC; Lin־CD14+HLA-DR־/lo, see
Figure 4A) was determined. Significantly higher levels
of circulating mMDSC were detected in CRPC patients
compared with age- and sex-matched healthy individ-
uals. Significant post-treatment increases in mMDSC
frequencies were observed (Figure 4B), yet these in-
creases were only modest and did not correlate with re-
sponse to treatment (not shown) or survival (Table 1).
In contrast, patients who displayed high pre-treatment
levels of mMDSC had a significantly shorter OS than pa-
tients who did not (Figure 4C, median survival 20 vs. 52
months, HR = 4.26, 95% CI = 1.37 - 13.25, p = 0.0046).
A myeloid marker profile of high DC activation and low
frequencies of MDSC is predictive for survival
To assess whether clinical prognosis impacted the puta-
tive predictive value for treatment outcome of any of the
identified myeloid parameters, the median Halabi Pre-
dicted Survival (HPS) was determined for the patient
groups above and below the designated cut-offs [29]. No
significant differences were observed, indicating that bet-
ter prognosis before treatment was not the determining
factor for any of these parameters (Table 1).
We previously identified a lymphoid biomarker profile
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10 vs. 18) 0.397 0.688 (0.299-1.582) 16.8 vs. 19.1 0.338
19 vs. 9) 0.0031 0.179 (0.057-0.560) 18.6 vs. 17.7 0.684
4 vs. 26) 0.739 1.226 (0.373-4.032) 14.2 vs. 19.0 0.168
9 vs. 19) 0.0749 0.469 (0.204-1.079) 20.1 vs. 17.4 0.192
8 vs. 11) 0.270 0.559 (0.198-1.572) 16.7 vs. 21.4 0.139
to pre-treatment values.
odel and the relative increments are given as percentage of
d given in months.
and considered significant when p < 0.05 (in bold).
for patients with biomarker increments above or under designated cut-offs.
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Figure 2 Increased monocyte activation following Prostate GVAX/ipilimumab therapy is associated with prolonged survival. Frequencies
and activation status of circulating CD14+ monocytes were determined before (w0), during (w4, w8, w12, w16, w20, w24) and after (fu) Prostate GVAX/
ipilimumab treatment by flowcytometric analysis. A) Mean percentage (of PBMC) ± SEM and B)mean activation ± SEM of CD14+ monocytes is shown
before, during and after Prostate GVAX/ipilimumab treatment for 28 patients, divided by clinical PSA response: partial PSA response (PR; black squares),
disease stabilization or (SD; white squares) or disease progression (PD; grey squares). Activation is given as med. Fluorescence Index (med. FI) and
calculated by dividing the med. fluorescence (med. fl) of CD40 antibody by the med. fl of the isotype control antibody. C) Kaplan Meier curve for
treatment-induced increases in activation of monocytes. Number of patients and corresponding median survival for each group are given. Differences
between pre- and on- or post-treatment were analyzed with the repeated measures ANOVA with a post-hoc Dunnett’s multiple comparisons test.
Differences were considered significant when p < 0.05, as indicated with asterisks (* p < 0.05, ** p < 0.01).
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[17]. When combining all predictive lymphoid [17] and
myeloid markers in an unsupervised cluster analysis, we
found a particularly strong association with prolonged
survival for patients displaying a combination of high
levels of on-treatment cDC1/cDC3/monocyte activation,
low pretreatment mMDSC rates and high pretreatment
frequencies of CD4+CTLA4+ T cells (designated clustered
group 2, median OS 46 months, see Figure 5A and 5B).
Nevertheless, patients with relatively high pretreatment
frequencies of CD4+CTLA4+ T cells showed significant
survival benefit whether these were accompanied by con-
certed high levels of on-treatment cDC1/cDC3/monocyte
activation and low pretreatment mMDSC rates or not
(designated clustered groups 2 + 1, median OS 40 months;
see Figure 5A and 5C).Discussion
PBDC and MDSC profiling of patients with CRPC re-
ceiving combined Prostate GVAX/ipilimumab treatment
revealed that PBDC and MDSC subsets were affected by
prostate GVAX/ipilimumab therapy, with on-treatment
increases in DC activation and mMDSC frequencies. Of
note, a myeloid profile of low pretreatment frequencies
of mMDSC and high treatment-induced cDC1, cDC3,
and monocyte activation levels demonstrated predictive
value for OS on treatment. As this was only a small ex-
ploratory study of 28 patients, no multivariate analyses
were performed and the candidate biomarkers should be
validated prospectively in larger randomized trials.
It has been reported that frequencies and activation
status of circulating DC are significantly lower in cancer
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Figure 3 PBDC activation in relation to immune-related adverse events (IRAE). Fold increase in activation of A) cDC1, B) cDC2, C) cDC3, D)
pDC and E) monocytes was determined at week 4 after start of prostate GVAX/ipilimumab treatment by dividing the median Fluorescence Index
(med. FI) of CD40 at week four (i.e. 2 vaccinations and 1 ipilimumab infusion) by the med. FI of CD40 at start of treatment and displayed for
patients that experienced IRAE or no IRAE during therapy. Differences in fold increase in activation between groups of patients were analyzed
with the two-sample Mann-Whitney U test. Differences were considered significant when p < 0.05, as indicated with the given p-value.
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cantly lower cDC1 frequencies and an inferior activation
state of cDC1, cDC2 and monocytes in mCRPC patients
(see Additional file 3: Figure S3A and B). Interestingly,
prostate GVAX/ipilimumab treatment resulted in a fur-
ther reduction of circulating cDC and pDC subsets, and
this reduction was paralleled by increases in their activa-
tion status. The observed activation may be explained by
the production of GM-CSF by the vaccine, as GM-CSF
has been described to activate DC in vivo [20,21]. Alter-
natively, or additionally, ipilimumab may have altered
DC activation state through blocking CTLA-4/B7 inter-
actions at the Treg/DC interface or by direct binding of
CTLA-4 on DC [30-32]. Nevertheless, a lack of associ-
ation between ipilimumab dose and DC activation seems
to support an overriding role for GVAX-derived GM-
CSF in this respect. The enhanced activation and simul-
taneous reduction of cDC and pDC subset frequencies
in blood is suggestive of their recruitment to effector
sites (e.g. tumor and vaccination sites). This hypothesis
is further supported by our own observation of en-
hanced recruitment of antigen-presenting cells to the
Prostate GVAX vaccination sites following repeatedvaccination (Van Mens et al, manuscript in preparation).
However, absolute PBDC subset numbers showed more
moderate decreases whereas they revealed a significant
on-treatment increase in cDC3. The latter fits well with
the inflammatory nature of cDC3 or SLAN-DC, being
mobilized by cytokines like GM-CSF [33].
MDSC represent a heterogeneous population of imma-
ture myeloid cells, and have been recognized to play an
important role in suppression of (anti-tumor) immune
responses. Elevated levels of either monocytoid or gran-
ulocytic MDSC have been observed in a variety of hu-
man cancers [34-38]. Moreover, their presence in
peripheral blood or at the tumor site has been linked
with poor prognosis and may thus serve as a prognostic
or predictive marker for clinical outcome [36,39-41]. In
keeping with previous findings, mCRPC patients displayed
significantly higher levels of mMDSC compared with age-
and sex-matched healthy controls (see Additional file 3:
Figure S3C). In fact, significantly prolonged OS was ob-
served for patients displaying low pre-treatment levels of
mMDSC, i.e. levels that were similar to those found in
healthy volunteers, suggesting that indeed mMDSC levels
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Figure 4 High pretreatment frequency of mMDSC is associated
with reduced OS. mMDSC frequencies were determined before
(week 0/visit 1 (w0v1)), during (w8v5, w16v9 and w24v13) and after
(follow-up (fu)) prostate GVAX/ipilimumab therapy by flow cytometry.
A) A representative analysis of Lin−CD14+HLA-DR−/lo mMDSC. B)
Percentage of mMDSC over follow-up. C) Kaplan meier curve for
pre-treatment frequencies of mMDSC. Number of patients and
corresponding median survival for each group are given. Differences
between pre- and on- or post-treatment were analyzed with the
repeated measures ANOVA with a post-hoc Dunnett’s multiple
comparisons test. Differences were considered significant when
p < 0.05, as indicated with asterisks (* p < 0.05, ** p < 0.01). Statistical
significance of the survival distribution was analyzed by log-rank
testing and indicated with the given p-value.
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predictive value of pre-treatment mMDSC frequencies for
outcome of tumor peptide vaccination therapy in patients
with renal cell cancer [39].Our data demonstrated modest increases of mMDSC
frequencies following multiple Prostate GVAX/ipilimu-
mab doses in a subgroup of patients. As described, in-
creases in the frequency of circulating MDSC can be
related to progression [39,42-44]. No such relation was
observed in our study, as no difference in mMDSC ex-
pansion was observed between PR, SD and PD patients
(not shown). The observed mMDSC expansion might
have been induced by the Prostate GVAX vaccine, since
GM-CSF-based vaccines have been shown to expand
MDSC in mice and man [22,23]. Perhaps surprisingly, the
post-vaccination increases of circulating mMDSC frequen-
cies did not impact survival in our study, suggesting that
prostate GVAX/ipilimumab therapy may reduce the sup-
pressive function of mMDSC. Indeed, reduction of MDSC
suppressive function has been described for CTLA-4
blockade therapy in an in vitro and in vivo murine ovarian
carcinoma model [24-26]. Moreover, as mMDSC have
been shown to further develop into more mature macro-
phage and DC-like cells [42], GM-CSF-driven differenti-
ation may have interfered with their suppressive ability.
A major problem in CTLA-4 blockade therapy is the
development of potentially life-threatening IRAE like
colitis, hepatitis, alveolitis and hypophysitis [45,46]. To
date, attempts to reduce the development of these IRAE
have been unsuccessful [47]. Therefore, it is important
to identify biomarkers for patient selection or develop
methods that enable the early detection of IRAE. Within
the myeloid compartment, no pre-treatment marker
with putative clinical value for IRAE risk prediction
could be identified. Yet, our data showed that the mag-
nitude of early (i.e. at week 4, after only one single ipili-
mumab administration) CD40 up-regulation on cDC1,
cDC3 and monocytes correlated with on-treatment
IRAE development. Unfortunately, the clinical applic-
ability of this on-treatment change as a marker for IRAE
risk is questionable, as there is considerable overlap for
CD40 activation levels on the indicated subsets between
the IRAE positive and negative group (Figure 3).
Our profiling data are consistent with clinical benefit
and survival advantage for patients with high DC activa-
tion and low levels of MDSC. These data echo our find-
ing of a predictive T cell profile of activated T cells and
low pre-treatment Treg frequencies in the same group
of patients [17], and are in line with an ever growing
number of studies stressing the importance of a pro-
inflammatory, non-suppressive immune status for optimal
efficacy of immunotherapy in cancer patients. Interest-
ingly, our unsupervised clustering analysis of combined
myeloid and lymphoid biomarkers indicates two, partially
overlapping, major populations with survival benefit:
1) patients with combined low pre-treatment frequen-
cies of mMDSC and high on-treatment cDC activation
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Figure 5 High on-treatment cDC1/cDC3/monocyte activation and low pretreatment mMDSC frequencies predict clinical benefit after
therapy. A) Unsupervised cluster analysis of the expression of the indicated treatment-induced and pre-treatment myeloid and lymphoid
markers. To identify clusters of correlated markers, hierarchical cluster analysis using TIGR software was performed, and average linkage analysis
was done by Pearson correlation analysis. Values of the treatment-induced and pre-treatment parameters are given relative to the cut-off value
(determined by Cox regression model as described in materials and methods); below cut-off in green and above cut-off in red. Kaplan Meier
curves for B) group 2 (with high on-treatment cDC1/cDC3/monocyte activation and low pretreatment mMDSC frequencies: highlighted by white
boxes in the heat plot) versus group 3 (with generally low on-treatment cDC1/cDC3/monocyte activation and high mMDSC frequencies) and
C) group 1 + 2 (with high pre-treatment frequencies of CD4+CTLA4+ T cells: lower white box in heat plot) versus group 3. Statistical significance
of the survival distribution was analyzed by log-rank testing and indicated with the given p-value. Number of patients and corresponding median
survival for each group are given.
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Whereas the latter biomarker profile may signal particular
susceptibility to check point inhibition [17], the first may
be representative of a favorable immune state and as such
hold predictive value for immunotherapy in general. These
profiles warrant further assessment and validation of their
utility for patient selection in other, preferably randomized,
clinical trials of GM-CSF-based therapy and/or CTLA-4
blockade or other forms of cancer immunotherapy.
Conclusions
This study provides evidence that circulating myeloid sub-
sets are affected by combined Prostate GVAX and ipilimu-
mab therapy and that a myeloid lineage profile of low
pretreatment mMDSC frequencies and high treatment-
induced cDC activation levels may contribute to the identi-
fication of patients with possible clinical benefit of Prostate
GVAX/ipilimumab treatment.
Methods
Prostate GVAX and ipilimumab
The Prostate GVAX vaccine is a cellular vaccine consist-
ing of two prostate cancer cell lines, LNCaP (CG8711)and PC-3 (CG1940), which have been transduced with
an adeno-associated viral vector to secrete GM-CSF.
These cell lines were propagated, frozen, and irradiated
to arrest further cell division [6,48]. The product was
stored and shipped in gaseous nitrogen phase, and admin-
istered within 60 minutes after thawing. All manufactur-
ing was conducted according to good manufacturing
practice. Ipilimumab (formerly MDX-010), a fully human
IgG1κ monoclonal antibody directed against CTLA-4, was
provided by Medarex/Bristol-Myers Squibb (Plainsboro,
NJ, USA).Study population and sampling of peripheral blood
As described [11], 28 chemonaive patients with asymp-
tomatic mCRPC received 13 bi-weekly vaccinations of the
Prostate GVAX vaccine and 6 four-weekly infusions of ipi-
limumab from the time of prime vaccination. In the first
12 patients, ipilimumab was administered at escalating
doses of 0.3, 1, 3 and 5 mg/kg (3 patients each). In the ex-
pansion phase, 16 additional patients were included at
3 mg/kg ipilimumab. This study is registered with the
Central Committee on Research involving Human Subjects
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gov, number NCT01510288.
Responses to treatment were defined as described [49].
In brief, PSA partial response (PR) was defined as >50%
PSA decline from baseline, which was confirmed by a
second PSA test 3 or more weeks later. PSA progressive
disease (PD) was defined as >25% PSA increase and an
absolute increase of 2 ng/ml or more from baseline,
whereas stable disease (SD) was defined as no PR and
no PD on treatment.
For immune monitoring, blood samples were taken
from the patients before start of therapy and every four
weeks thereafter until four weeks after the last treat-
ment (i.e. follow-up (fu)). Peripheral blood mononuclear
cells (PBMC) were isolated by density centrifugation
(NycomedAS, Oslo, Norway). PBMC were either directly
used for PBDC or monocyte analysis or cryopreserved for
later MDSC flow cytometric analysis.
Antibodies and 4-color flow cytometry
PBDC and MDSC frequencies and activation status were
assessed before, during and after treatment by flow cy-
tometry staining as described [17]. Cell surface antibody
staining of PBMC was performed in PBS/0.1% BSA/
0.02% Sodium-Azide (hereafter referred to as FACS buf-
fer) for 30 minutes at 4°C. The following antibodies were
used: fluorescein isothiocyanate- (FITC), phycoerythrin-
(PE), peridinin chlorophyll protein-Cy5.5- (PerCP) or
allophycocyanin (APC)-labeled Abs directed against hu-
man CD3, CD11c, CD14, CD16, CD19, CD33, CD56,
CD123 and HLA-DR (all BD Bioscience), CD40 (Beckman
Coulter, Marseille, France), Fab-M-FITC (Southern Bio-
tec, Birmingham, AL) and blood DC antigens BDCA1,
BDCA2, BDCA3 (all from Milteny Biotec, Bergisch-
Gladbach, Germany) and MDC8 (a kind gift from Dr.
E.P. Rieber, Dresden, Germany) and matching isotype
control antibodies. Stained cells were analyzed on aFACS-
calibur (BD Biosciences) using Cell Quest software. Events
collected were 120,000-150,000 per sample.
PBDC and MDSC subset and activation definitions
PBDC frequencies were determined on the basis of ex-
pression of BDCA or MDC8 markers: two major mye-
loid or conventional DC (cDC) subsets as recognized
by the Nomenclature Committee of the International
Union of Immunological Societies were identified as
CD11chiCD19−CD14−BDCA-1/CD1c+ DC (designated
cDC1) and as CD11c+CD14−BDCA-3+ DC (designated
cDC2) [50,51]; in addition we assessed frequencies of a
third myeloid subset, designated cDC3, and defined as
CD11c+CD14loMDC8+ DC (also known as 6-sulfo Lac-
NAc+ non-classical monocytes or SLAN-DC [33,52])
as well as plasmacytoid DC (pDC), defined as
CD11c−CD14−CD123hiBDCA-2+ [28]. Classic monocyteswere defined as CD11chiCD14hi (highly positive; see
also Additional file 2: Figure S2). Monocytoid MDSC
(mMDSC) were defined as Lin−CD14+HLA-DRneg/lo
[28] (see also Figure 4A). For all the above mentioned
populations a live gate was used based on FSC-SSC
properties of the lymphocyte and monocyte populations.
Activation status of above mentioned cDC, pDC and
monocyte subsets was determined by calculating the me-
dian Fluorescence Index (med. FI) of CD40 expression by
dividing the med. fluorescence (Med. fl) of the CD40 anti-
body by the med. fl of the isotype-control antibody.
Statistical analyses
Differences between immune parameters before treatment
(w0v1; w =week; v = visit; i.e. baseline levels) and during
and/or after treatment (w4v3, w8v5, w12v7, w16v9,
w20v11, w24v13 and follow up [fu, i.e. 1 month after last
Prostate GVAX and 2 months after last ipilimumab ad-
ministration]) were analyzed with the repeated measures
ANOVA with a post-hoc Dunnett’s multiple comparisons
test. To determine whether the identified immune param-
eters were indicative for response to treatment or useful
for survival prediction, optimal cut-off points were deter-
mined by Cox regression analysis, according to which pa-
tients were subsequently divided into two groups. OS for
the two groups was plotted using the Kaplan-Meier
method and statistical significance of the survival distribu-
tion was analyzed by log-rank testing. To analyze whether
prognosis impacted the value of the identified response/
survival parameters, the median Halabi Predicted Survival
(HPS) was also determined for both groups ([29,53]; see
also Table 1). Differences in HPS between groups of pa-
tients and in parameters between prostate cancer patients
and age and sex-matched healthy volunteers were ana-
lyzed with the two-sample Mann-Whitney U or the
Fisher’s exact test (both two-tailed). Above listed statis-
tical analyses were performed either with Prism GraphPad
or SPSS software. Differences were considered significant
when p < 0.05. To identify clusters of correlated markers,
hierarchical cluster analysis using TIGR software was per-
formed and complete linkage analysis was done by Pearson
correlation analysis. For this purpose, the values of the
treatment-induced and pre-treatment parameters were
taken for each patient, and divided by the cut-off value, after
which the resulting ratios were log-transformed (base 2).
Three patients were excluded from this analysis since <70%
of the analyzed biomarkers were available for these patients
due to withdrawal from the study or sampling failure.
Additional files
Additional file 1: Figure S1. IRAE in relation to treatment response and
survival. A) Distribution of IRAE within the different treatment response
groups (i.e. partial response (PR), Stable Disease (SD) and Progressive
Santegoets et al. Journal for ImmunoTherapy of Cancer 2014, 2:31 Page 10 of 12
http://www.immunotherapyofcancer.org/content/2/1/31Disease (PD)) is given. Black bars: patients experiencing IRAE and white/
open bars: patients without IRAE during treatment. B) Kaplan Meier
curve for the patients that experienced IRAE. Number of patients and
corresponding median survival for each group are given. Differences in
distribution of IRAE between treatment response groups were analyzed
with a two-tailed Fisher’s exact test. Statistical significance of the survival
distribution was analyzed by log-rank testing. Differences were considered
significant when p < 0.05.
Additional file 2: Figure S2. Peripheral Blood DC (PBDC) gating
strategy. A) First, live cells were gated based on FSC-SSC properties of
the lymphocyte and monocyte populations (not shown), after which the
cDC1, cDC2, cDC3 and pDC populations were identified through BDCA1
(and CD19−, not shown), BDCA3, MDC8 and BDCA2 expression. By
backgating on CD11c and CD14 as indicated, the identity of the different
DC subsets was confirmed. Activation status of abovementioned cDC,
pDC and monocyte subsets was determined by calculating the median
Fluorescence Index (med. FI) of CD40 expression by dividing the med.
fluorescence (Med. fl) of the CD40 antibody by the med. fl of the
isotype-control antibody. B) Isotype control and CD40 histograms are
depicted for the cDC1 (left) and cDC3 (right) subsets at week (w) 0 visit
(v) 1 (i.e. baseline) and w4v3 for a representative patient.
Additional file 3: Figure S3. PBDC frequencies and activation status
and MDSC frequencies in mCRPC patients and healthy individuals.
Frequencies of cDC, pDC, monocytes and gMDSC and mMDSC subsets,
and activation status of cDC, pDC and monocytes was determined in
mCRPC patients before prostate GVAX/ipilimumab therapy and age- and
sex-matched healthy donors (HD). Percentage A) and activation status B)
of cDC1, cDC2, cDC3, pDC and monocytes and percentage of C) mMDSC
are shown. Differences in percentage or activation between mCRPC and
HD were analyzed with the two-sample Mann-Whitney U test. Differences
were considered significant when p < 0.05, as indicated with the given
p-value.
Additional file 4: Figure S4. Differential leukocyte analysis in mCRPC
patients before and during prostate GVAX/ipilimumab therapy. Absolute
lymphocytes (white squares) and monocyte (black squares) counts were
determined before (week 0/visit 1 (w0v1)), during (w4v3, w8v5, w16v9)
and after (follow-up (fu)) prostate GVAX/ipilimumab therapy. Mean
absolute counts ± SEM is given in 10e6 per ml of blood for lymphocytes
(white squares), monocytes (black squares) and the sum of lymphocytes
and monocytes (i.e. PBMC, grey squares). Differences between pre- and
on- or post-treatment were analyzed with the repeated measures ANOVA
with a post-hoc Dunnett’s multiple comparisons test. Differences were
considered significant when p < 0.05, as indicated with an asterisk
(* p < 0.05, ** p < 0.01).
Abbreviations
cDC: Conventional dendritic cell; CTLA-4: CTL antigen-4; CRCP: Castration
resistant prostate cancer; fu: Follow-up; HPS: Halabi predicted survival;
IRAE: Immune related adverse events; MDSC: Myeloid-derived suppressor cell;
OS: Overall survival; pDC: Plasmacytoid dendritic cell; PD: Progressive disease;
PR: Partial response; SD: Stable disease.
Competing interests
IL owns stock and/or stock options from Bristol-Myers Squibb. AJMvdE and
WRG have served as consultants and received honoraria from Bristol-Myers
Squibb. TDG and WRG received an educational grant from Cell Genesys Inc.
All other authors declare that they have no competing interests.
Authors’ contributions
SJAMS designed and performed research, analyzed data and drafted and
co-wrote the manuscript. AGMS performed research and analyzed data. SML
performed research. HG was the responsible research nurse for this trial and
collected PBMC samples. KJ, NS, KH, IL provided reagents and co-designed
the clinical study. WRG and AJMvdE treated patients, co-designed, and
served as principal investigators for, the clinical trial. AJMvdE, RJS and WRG
co-wrote the manuscript. TDdG designed research, analyzed data and
drafted and co-wrote the manuscript. All authors read and approved the
final manuscript.Acknowledgements
This research was financially supported by awards and grants from the
Prostate Cancer Foundation (PCF Competitive Research Award to T.D.G.),
StichtingVUmc-CCA, and the Dutch Cancer Society (KFW; VU 2006-3697).
Author details
1Department of Medical Oncology, VU University Medical Center, Cancer
Center Amsterdam, Amsterdam, The Netherlands. 2Department of Pathology,
VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The
Netherlands. 3Cell Genesys Inc, South San Francisco, CA, USA. 4Medarex,
Bloomsbury, NJ/Bristol-Myers Squibb Company, Wallingford, CT, USA.
Received: 9 April 2014 Accepted: 6 August 2014
References
1. Drake CG: Prostate cancer as a model for tumour immunotherapy. Nat
Rev Immunol 2010, 10:580–593.
2. Tannock IF, De WR, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S,
Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA:
Docetaxel plus prednisone or mitoxantrone plus prednisone for
advanced prostate cancer. N Engl J Med 2004, 351:1502–1512.
3. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern
CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF:
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
N Engl J Med 2010, 363:411–422.
4. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M,
Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL,
Godfrey WR: Overall survival analysis of a phase II randomized controlled
trial of a Poxviral-based PSA-targeted immunotherapy in metastatic
castration-resistant prostate cancer. J Clin Oncol 2010, 28:1099–1105.
5. Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, Suri KB,
Levy C, Allen T, Mavroukakis S, Lowy I, White DE, Rosenberg SA: Ipilimumab
(anti-CTLA4 antibody) causes regression of metastatic renal cell cancer
associated with enteritis and hypophysitis. J Immunother 2007, 30:825–830.
6. Small EJ, Sacks N, Nemunaitis J, Urba WJ, Dula E, Centeno AS, Nelson WG,
Ando D, Howard C, Borellini F, Nguyen M, Hege K, Simons JW: Granulocyte
macrophage colony-stimulating factor–secreting allogeneic cellular
immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res
2007, 13:3883–3891.
7. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB,
Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den
Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D,
Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS,
Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ: Improved survival with
ipilimumab in patients with metastatic melanoma. N Engl J Med 2010,
363:711–723.
8. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T,
Henry-Spires R, Macrae S, Willman A, Padera R, Jaklitsch MT, Shankar S,
Chen TC, Korman A, Allison JP, Dranoff G: Biologic activity of cytotoxic T
lymphocyte-associated antigen 4 antibody blockade in previously
vaccinated metastatic melanoma and ovarian carcinoma patients.
Proc Natl Acad Sci U S A 2003, 100:4712–4717.
9. Fong L, Kwek SS, O’Brien S, Kavanagh B, McNeel DG, Weinberg V, Lin AM,
Rosenberg J, Ryan CJ, Rini BI, Small EJ: Potentiating endogenous antitumor
immunity to prostate cancer through combination immunotherapy with
CTLA4 blockade and GM-CSF. Cancer Res 2009, 69:609–615.
10. Hurwitz AA, Yu TF, Leach DR, Allison JP: CTLA-4 blockade synergizes with
tumor-derived granulocyte-macrophage colony-stimulating factor for
treatment of an experimental mammary carcinoma. Proc Natl Acad Sci
U S A 1998, 95:10067–10071.
11. van den Eertwegh AJ, Versluis J, van den Berg HP, Santegoets SJ, van
Moorselaar RJ, van der Sluis TM, Gall HE, Harding TC, Jooss K, Lowy I, Pinedo
HM, Scheper RJ, Stam AG, von Blomberg BM, de Gruijl TD, Hege K, Sacks N,
Gerritsen WR: Combined immunotherapy with granulocyte-macrophage
colony-stimulating factor-transduced allogeneic prostate cancer cells
and ipilimumab in patients with metastatic castration-resistant prostate
cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012, 13:509–517.
12. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, Carbone DP,
Gabrilovich DI: Clinical significance of defective dendritic cell
differentiation in cancer. Clin Cancer Res 2000, 6:1755–1766.
Santegoets et al. Journal for ImmunoTherapy of Cancer 2014, 2:31 Page 11 of 12
http://www.immunotherapyofcancer.org/content/2/1/3113. Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP: Decreased
antigen presentation by dendritic cells in patients with breast cancer.
Clin Cancer Res 1997, 3:483–490.
14. Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, Carbone DP:
Vascular endothelial growth factor inhibits the development of dendritic
cells and dramatically affects the differentiation of multiple
hematopoietic lineages in vivo. Blood 1998, 92:4150–4166.
15. Della BS, Gennaro M, Vaccari M, Ferraris C, Nicola S, Riva A, Clerici M, Greco
M, Villa ML: Altered maturation of peripheral blood dendritic cells in
patients with breast cancer. Br J Cancer 2003, 89:1463–1472.
16. Boissel N, Rousselot P, Raffoux E, Cayuela JM, Maarek O, Charron D, Degos L,
Dombret H, Toubert A, Rea D: Defective blood dendritic cells in chronic
myeloid leukemia correlate with high plasmatic VEGF and are not
normalized by imatinib mesylate. Leukemia 2004, 18:1656–1661.
17. Santegoets SJ, Stam AG, Lougheed SM, Gall H, Scholten PE, Reijm M, Jooss
K, Sacks N, Hege K, Lowy I, Cuillerot JM, von Blomberg BM, Scheper RJ, van
den Eertwegh AJ, Gerritsen WR, de Gruijl TD: T cell profiling reveals high
CD4 + CTLA-4 + T cell frequency as dominant predictor for survival after
prostate GVAX/ipilimumab treatment. Cancer Immunol Immunother 2013,
62:245–256.
18. MacDonald KP, Munster DJ, Clark GJ, Dzionek A, Schmitz J, Hart DN:
Characterization of human blood dendritic cell subsets. Blood 2002,
100:4512–4520.
19. Rissoan MC, Soumelis V, Kadowaki N, Grouard G, Briere F, de Waal MR, Liu
YJ: Reciprocal control of T helper cell and dendritic cell differentiation.
Science 1999, 283:1183–1186.
20. Haddad D, Ramprakash J, Sedegah M, Charoenvit Y, Baumgartner R, Kumar
S, Hoffman SL, Weiss WR: Plasmid vaccine expressing granulocyte-
macrophage colony-stimulating factor attracts infiltrates including
immature dendritic cells into injected muscles. J Immunol 2000,
165:3772–3781.
21. Pan PY, Li Y, Li Q, Gu P, Martinet O, Thung S, Chen SH: In situ recruitment
of antigen-presenting cells by intratumoral GM-CSF gene delivery.
Cancer Immunol Immunother 2004, 53:17–25.
22. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I: High-dose
granulocyte-macrophage colony-stimulating factor-producing vaccines
impair the immune response through the recruitment of myeloid sup-
pressor cells. Cancer Res 2004, 64:6337–6343.
23. Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, Castelli C, Mariani L,
Parmiani G, Rivoltini L: Identification of a new subset of myeloid
suppressor cells in peripheral blood of melanoma patients with
modulation by a granulocyte-macrophage colony-stimulation factor-
based antitumor vaccine. J Clin Oncol 2007, 25:2546–2553.
24. Suzuki J, Ricordi C, Chen Z: Immune tolerance induction by integrating
innate and adaptive immune regulators. Cell Transplant 2010, 19:253–268.
25. Yang R, Cai Z, Zhang Y, Yutzy WH, Roby KF, Roden RB: CD80 in immune
suppression by mouse ovarian carcinoma-associated Gr-1 + CD11b +
myeloid cells. Cancer Res 2006, 66:6807–6815.
26. Liu Y, Yu Y, Yang S, Zeng B, Zhang Z, Jiao G, Zhang Y, Cai L, Yang R:
Regulation of arginase I activity and expression by both PD-1 and
CTLA-4 on the myeloid-derived suppressor cells. Cancer Immunol
Immunother 2009, 58:687–697.
27. van Cruijsen H, Hoekman K, Stam AG, van den Eertwegh AJ, Kuenen BC,
Scheper RJ, Giaccone G, de Gruijl TD: Defective differentiation of myeloid
and plasmacytoid dendritic cells in advanced cancer patients is not
normalized by tyrosine kinase inhibition of the vascular endothelial
growth factor receptor. Clin Dev Immunol 2007, 2007:17315.
28. van Cruijsen H, van der Veldt AA, Vroling L, Oosterhoff D, Broxterman HJ,
Scheper RJ, Giaccone G, Haanen JB, van den Eertwegh AJ, Boven E,
Hoekman K, de Gruijl TD: Sunitinib-induced myeloid lineage redistribution
in renal cell cancer patients: CD1c + dendritic cell frequency predicts
progression-free survival. Clin Cancer Res 2008, 14:5884–5892.
29. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine
EG, Blumenstein BA, Vogelzang NJ: Prognostic model for predicting
survival in men with hormone-refractory metastatic prostate cancer.
J Clin Oncol 2003, 21:1232–1237.
30. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z,
Nomura T, Sakaguchi S: CTLA-4 control over Foxp3+ regulatory T cell
function. Science 2008, 322:271–275.
31. Han Y, Chen Z, Yang Y, Jiang Z, Gu Y, Liu Y, Lin C, Pan Z, Yu Y, Jiang M,
Zhou W, Cao X: Human CD14 CTLA-4 regulatory dendritic cells suppressT cell response via CTLA-4-dependent IL-10 and IDO production in
hepatocellular carcinoma. Hepatology 2014, 59:567–579.
32. Laurent S, Carrega P, Saverino D, Piccioli P, Camoriano M, Morabito A, Dozin
B, Fontana V, Simone R, Mortara L, Mingari MC, Ferlazzo G, Pistillo MP:
CTLA-4 is expressed by human monocyte-derived dendritic cells and
regulates their functions. Hum Immunol 2010, 71:934–941.
33. Schakel K, Kannagi R, Kniep B, Goto Y, Mitsuoka C, Zwirner J, Soruri A, Von
KM, Rieber E: 6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-
1, defines an inflammatory type of human dendritic cells. Immunity 2002,
17:289–301.
34. Liu CY, Wang YM, Wang CL, Feng PH, Ko HW, Liu YH, Wu YC, Chu Y, Chung
FT, Kuo CH, Lee KY, Lin SM, Lin HC, Wang CH, Yu CT, Kuo HP: Population
alterations of L-arginase- and inducible nitric oxide synthase-expressed
CD11b+/CD14(-)/CD15+/CD33+ myeloid-derived suppressor cells and
CD8+ T lymphocytes in patients with advanced-stage non-small cell
lung cancer. J Cancer Res Clin Oncol 2010, 136:35–45.
35. Vuk-Pavlovic S, Bulur PA, Lin Y, Qin R, Szumlanski CL, Zhao X, Dietz AB:
Immunosuppressive CD14 + HLA-DRlow/- monocytes in prostate cancer.
Prostate 2010, 70:443–455.
36. Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW: Elevated
myeloid-derived suppressor cells in pancreatic, esophageal and gastric
cancer are an independent prognostic factor and are associated with
significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol
Immunother 2011, 60:1419–1430.
37. Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Kruger C, Manns MP, Greten
TF, Korangy F: A new population of myeloid-derived suppressor cells in
hepatocellular carcinoma patients induces CD4 (+) CD25 (+) Foxp3 (+) T
cells. Gastroenterology 2008, 135:234–243.
38. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J,
McDermott D, Quiceno D, Youmans A, O’Neill A, Mier J, Ochoa AC:
Arginase-producing myeloid suppressor cells in renal cell carcinoma
patients: a mechanism of tumor evasion. Cancer Res 2005, 65:3044–3048.
39. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C,
Staehler M, Brugger W, Dietrich PY, Mendrzyk R, Hilf N, Schoor O, Fritsche J,
Mahr A, Maurer D, Vass V, Trautwein C, Lewandrowski P, Flohr C, Pohla H,
Stanczak JJ, Bronte V, Mandruzzato S, Biedermann T, Pawelec G,
Derhovanessian E, Yamagishi H, Miki T, Hongo F, Takaha N, et al:
Multipeptide immune response to cancer vaccine IMA901 after single-
dose cyclophosphamide associates with longer patient survival. Nat Med
2012, 18:1254–1261.
40. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ,
Montero AJ: Increased circulating myeloid-derived suppressor cells
correlate with clinical cancer stage, metastatic tumor burden, and
doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol
Immunother 2009, 58:49–59.
41. Johansson CC, Mougiakakos D, Trocme E, II-Ericsson C, Economou MA,
Larsson O, Seregard S, Kiessling R: Expression and prognostic significance
of iNOS in uveal melanoma. Int J Cancer 2010, 126:2682–2689.
42. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V: Coordinated regulation of
myeloid cells by tumours. Nat Rev Immunol 2012, 12:253–268.
43. Gorczyca W, Sun ZY, Cronin W, Li X, Mau S, Tugulea S: Immunophenotypic
pattern of myeloid populations by flow cytometry analysis. Methods Cell
Biol 2011, 103:221–266.
44. Duffy A, Zhao F, Haile L, Gamrekelashvili J, Fioravanti S, Ma C, Kapanadze T,
Compton K, Figg WD, Greten TF: Comparative analysis of monocytic and
granulocytic myeloid-derived suppressor cell subsets in patients with
gastrointestinal malignancies. Cancer Immunol Immunother 2012,
62:299–307.
45. Bouwhuis MG, Ten Hagen TL, Suciu S, Eggermont AM: Autoimmunity and
treatment outcome in melanoma. Curr Opin Oncol 2011, 23:170–176.
46. Weber J: Ipilimumab: controversies in its development, utility and
autoimmune adverse events. Cancer Immunol Immunother 2009,
58:823–830.
47. Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, Ridolfi R, Assi H,
Maraveyas A, Berman D, Siegel J, O’Day SJ: A randomized, double-blind,
placebo-controlled, phase II study comparing the tolerability and efficacy
of ipilimumab administered with or without prophylactic budesonide in
patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009,
15:5591–5598.
48. Simons JW, Carducci MA, Mikhak B, Lim M, Biedrzycki B, Borellini F, Clift SM,
Hege KM, Ando DG, Piantadosi S, Mulligan R, Nelson WG: Phase I/II trial of
Santegoets et al. Journal for ImmunoTherapy of Cancer 2014, 2:31 Page 12 of 12
http://www.immunotherapyofcancer.org/content/2/1/31an allogeneic cellular immunotherapy in hormone-naive prostate cancer.
Clin Cancer Res 2006, 12:3394–3401.
49. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA,
Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch
E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M:
Design and end points of clinical trials for patients with progressive
prostate cancer and castrate levels of testosterone: recommendations of
the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008,
26:1148–1159.
50. Dzionek A, Fuchs A, Schmidt P, Cremer S, Zysk M, Miltenyi S, Buck DW,
Schmitz J: BDCA-2, BDCA-3, and BDCA-4: three markers for distinct
subsets of dendritic cells in human peripheral blood. J Immunol 2000,
165:6037–6046.
51. Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, Leenen
PJ, Liu YJ, MacPherson G, Randolph GJ, Scherberich J, Schmitz J, Shortman
K, Sozzani S, Strobl H, Zembala M, Austyn JM, Lutz MB: Nomenclature of
monocytes and dendritic cells in blood. Blood 2010, 116:e74–e80.
52. Schakel K, Mayer E, Federle C, Schmitz M, Riethmuller G, Rieber EP: A novel
dendritic cell population in human blood: one-step immunomagnetic
isolation by a specific mAb (M-DC8) and in vitro priming of cytotoxic T
lymphocytes. Eur J Immunol 1998, 28:4084–4093.
53. Halabi S, Lin CY, Kelly WK, Fizazi KS, Moul JW, Kaplan EB, Morris MJ, Small EJ:
Updated prognostic model for predicting overall survival in first-line
chemotherapy for patients with metastatic castration-resistant prostate
cancer. J Clin Oncol 2014, 32:671–677.
doi:10.1186/s40425-014-0031-3
Cite this article as: Santegoets et al.: Myeloid derived suppressor and
dendritic cell subsets are related to clinical outcome in prostate cancer
patients treated with prostate GVAX and ipilimumab. Journal for
ImmunoTherapy of Cancer 2014 2:31.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
